Genprex to progress Phase I/II trial of non-small cell lung cancer therapy

Genprex has received approval from the Safety Review Committee (SRC) to advance the Phase I/II Acclaim-1 clinical trial of Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), plus AstraZeneca’s Tagrisso (osimertinib), for treating late-stage, non-small cell lung cancer (NSCLC).